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Abstract. 
Myelination in the peripheral nervous system (PNS) is controlled by both positive and 
negative regulators within Schwann cells to ensure timely onset and correct myelin 
thickness for saltatory conduction by neurons. Transcription factors such as Sox10, 
Oct6 and Krox20 form a positive regulatory network, whereas negative regulators 
such as cJun and Sox2 oppose myelination in Schwann cells. The role of the p38 
mitogen activated protein kinase (MAPK) pathway has been studied in PNS 
myelination, but its precise function remains unclear, with both positive and negative 
effects of p38 activity reported upon both myelination and processes of nerve repair. 
To clarify the role of p38 MAPK in the PNS, we have analysed mice with a Schwann 
cell-specific ablation of the major p38 isoform, p38alpha. In line with previous 
findings of an inhibitory role for p38 MAPK, we observe acceleration of post-natal 
myelination in p38alpha null nerves, a delay in myelin down-regulation following 
injury, together with a small increase in levels of re-myelination following injury. 
Finally we explored roles for p38alpha in controlling axonal regeneration and 
functional repair following PNS injury and observe that loss of p38 function on 
Schwann cells does not appear to affect these processes as previously reported.  
These studies therefore provide further proof for a role of p38 MAPK signalling in the 
control of myelination by Schwann cells in the PNS, but do not show an apparent  
role for signalling by this MAP kinase in Schwann cells controlling other elements of 
Wallerian degeneration and functional repair following injury. 
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Introduction. 
Schwann cells are the myelinating glia of the peripheral nervous system and the 
insulating myelin they provide allows the saltatory conduction of large diameter 
axons. The correct control of both the initiation and extent of myelination involves a 
number of positive and negative regulators and signalling pathways that act to 
preserve peripheral nerve function and homeostasis. Positive regulators that have 
been identified include the transcription factors Krox20, Oct6, Sox10, NFATC4 and 
YY1 (Topilko et al. 1994, Parkinson et al. 2004, Jaegle et al. 1996, He et al. 2010, 
Kao et al. 2009, Finzsch et al. 2010, Svaren & Meijer 2008), whereas negative 
regulation of myelination is controlled by transcription factors such as  cJun, Sox2 
and Pax3 (Parkinson et al. 2008, Le et al. 2005, Jessen & Mirsky 2008, Doddrell et 
al. 2012). As well as through transcriptional control, regulation of mitogen activated 
protein kinase (MAPK) signalling in Schwann cells has been shown to both positively 
and negatively regulate the control of myelination. Analysis of ERK1/ 2 MAP kinase 
mutants in Schwann cells has been shown that signalling through this pathway is 
required for normal myelination by Schwann cells (Ishii et al. 2013, Newbern et al. 
2011, Sheean et al. 2014). Conversely, activation of ERK1/2 signalling using a 
tamoxifen-regulated Raf-TR molecule in Schwann cells is sufficient to trigger  de-
myelination of Schwann cells in the absence of axonal damage (Harrisingh et al. 
2004, Napoli et al. 2012). For signalling through the PI-3 kinase pathway, both in 
vitro and in vivo studies have shown both a requirement for signalling through this 
pathway and that raised PI-3 kinase signalling in Schwann cells leads to increased 
myelin thickness in the PNS (Maurel & Salzer 2000, Ogata et al. 2004, Cotter et al. 
2010, Fledrich et al. 2014, Domenech-Estevez et al. 2016).  In addition to this, the 
p38 MAPK signalling pathway has also been identified as a strong regulator of both 
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Schwann cell behaviour and myelination in a number of in vitro and in vivo studies 
utilising chemical inhibitors of p38 MAP kinase activity. Our own previous findings 
(Yang et al. 2012), using both p38 inhibitors in vitro and in vivo and using specific 
activation of p38 signalling in vitro have shown an inhibitory effect of p38 signalling in 
controlling Schwann cell myelination. However other studies, using Schwann 
cell/dorsal root ganglion (SC/DRG) neuron co-cultures, have shown that blocking 
p38 MAPK activity at the same time as inducing myelination in these culture  inhibits 
Schwann cell myelination (Fragoso et al. 2003, Hossain et al. 2012). In other 
experiments using the SD-169 p38 inhibitor, in vivo experiments have identified 
positive effects of global p38 inhibition upon axonal regeneration and maturation 
following PNS injury (Myers et al. 2003).  
There are four isoforms of p38 MAPK, , ,  and  (Nebreda & Porras 2000), and 
although chemical  inhibitors such as SB202190, SB203580 are specific for  and  
isoforms, there is still an issue with ‘off-target’ effects of such compounds (Davies et 
al. 2000, Bain et al. 2007) and that, in SC/DRG co-cultures, which may not fully 
mimic processes of myelination in vivo, the effects of p38 inhibition on Schwann cells 
cannot be completely differentiated from those on the DRG neurons. In order to try 
and address these issues, Kato et al used a transgenic mouse model with a mutation 
in the p38 docking site, reported to reduce p38 MAP kinase activity. Analysis of 
these mice is, however, complicated by the fact that the mutation is present in all cell 
types within the nerve and, as complete p38 loss is embryonic lethal, only 
heterozygous mice with reduced p38 activity could be analysed in these 
experiments (Kato et al. 2013, Adams et al. 2000, Allen et al. 2000, Mudgett et al. 
2000). 
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In order to fully characterise the role of p38 MAPK activity within Schwann cells in 
controlling myelination and PNS repair, we have generated and analysed a Schwann 
cell-specific null for the major p38 isoform, p38In line with our previous findings, 
that p38 MAPK activity is a negative regulator of myelination (Yang et al. 2012), we 
observed both an earlier onset of myelination in the PNS and a delayed loss of 
myelin in Schwann cells following injury and loss of axonal contact; we also observe 
a slight, but non-significant,  increase in myelin thickness of regenerated axons 
following a crush injury. 
 In contrast to previous studies on axonal regeneration and the immune response 
following injury, we find no changes in the rates of axonal regeneration and 
functional repair following injury in nerves containing p38 null Schwann cells. 
Similarly, we find no changes in the proliferation of Schwann cells or numbers of 
macrophages recruited to the nerve following injury. Thus, although we can confirm 
a negative role for p38 MAPK activity in regulating myelination, these findings 
suggest that previously observed effects upon the immune response, axonal 
regeneration and repair following injury appear to be either due to the effects of p38 
inhibition on other cell types within the nerve, or are perhaps due to the non-
specificity of the p38 MAPK chemical inhibitors used in these previous studies. 
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Materials and Methods. 
Transgenic mice. 
All animal experiments were carried out in strict accordance with the UK Home 
Office regulations under the Animals (Scientific Procedures) Act of 1986. All 
experiments have been approved by the Plymouth University Animal Welfare and 
Ethical Review Board. Mice with a conditional p38 alpha () allele, p38fl/fl, have 
been previously described; CRE mediated recombination deletes exons 2 and 3 of 
the coding sequence generating p38 null cells (Heinrichsdorff et al. 2008). p38fl/fl 
animals were crossed with mice carrying the mP0TOTA-CRE (P0-CRE) transgene 
(Feltri et al. 1999) to generate p38fl/fl CRE- controls and p38fl/fl CRE+ Schwann 
cell-specific p38 null animals; both male and female animals were used in this study 
in approximately equal numbers with appropriate littermate age and sex-matched 
controls.  Animals were genotyped as previously described (Truett et al. 2000, Feltri 
et al. 1999, Heinrichsdorff et al. 2008). Mice were housed in a 12 hour light/dark 
cycle with ad libitum access to food and water.  p38fl/fl CRE- controls and p38fl/fl 
CRE+ null animals were born with the expected Mendelian ratios and no apparent 
physiological differences were observed between the two groups of animals. 
Sciatic nerve injury and assessment of functional recovery. 
Sciatic nerve injury, cut or crush, was carried out in adult animals under isoflurane 
anaesthesia as previously described (Dun & Parkinson 2015) and nerve samples 
taken at various timepoints following injury; contralateral uninjured nerves were used 
as controls. The mouse static sciatic index (SSI) measurement (Baptista et al. 2007)  
was used to assess recovery of sensory-motor co-ordination in animals at timepoints 
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following sciatic nerve injury. The evaluation of SSI values was made by an 
individual blinded to the genotype of the animal under test. 
Electron Microscopy. 
Samples for low vacuum (LV) scanning or transmission electron microscopy 
(SEM/TEM) were fixed in glutaraldehyde and embedded in resin blocks. For LV-SEM 
sample block surfaces were polished and analysed using a JEOL 6610 LV-SEM 
machine. For TEM, ultrathin sections were prepared, stained and visualised using a 
JEOL 1400 microscope. Myelin thickness or G ratio (myelin thickness/myelin + axon 
thickness) measurements were made from at least 200 myelinated fibres from the 
same area of sciatic nerve per animal at stated timepoints. Unless otherwise stated, 
n=3 mice of each genotype were used for each measurement of myelin thickness/ G 
ratio at each developmental age or timepoint following injury.  Measurements of axon 
and myelinated fibre (axon + myelin) diameter were made using ImageJ software. 
Immunocytochemistry, wholemount staining, Schwann cell culture and western 
blotting. 
Nerve samples were fixed in 4% paraformaldehyde/PBS overnight, cryoprotected in 
30% sucrose/PBS overnight at 4°C, and embedded in Optimal Cutting Temperature 
(OCT) compound and frozen for cryosectioning. Sections for immunostaining (10µm 
thickness) were cut from the same area of nerve for each sample using a Leica 
CM1860 UV cryostat. Sections were washed in PBS and blocked in either antibody 
diluting solution (Parkinson et al. 2004) or 10% goat serum/PBS, supplemented with 
0.2% Triton X-100 before addition of primary antibody. A two or three layer labelling 
system was used, either directly fluorophore conjugated secondary antibody or a 
biotinylated secondary antibody followed by a streptavidin fluorophore conjugate. 
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Samples were counterstained with Hoechst stain to reveal nuclei.  Wholemount 
staining of nerve samples after injury was performed as previously described (Dun & 
Parkinson 2015). The following primary antibodies were used for 
immunofluorescence staining at the indicated dilutions: Neurofilament (NF-200) 
heavy 200 kDa (1/500, Abcam ab4680), Iba1 (1/300, WAKO 019-19741), Ki67 
(1/200, Abcam ab15580) and Sox10 (1/100, R & D systems AF2864) 
Schwann cells were prepared from post-natal day 3-5 rats using serum purification 
and maintained in defined medium prior to lysing for western blot (Brockes et al. 
1979, Jessen et al. 1994, Parkinson et al. 2004).For western blotting of nerve 
samples, control and injured nerves were snap frozen in liquid nitrogen and stored at 
-80oC before extraction. Sample extraction, protein gel electrophoresis and analysis 
were all as previously described (Parkinson et al. 2004, Parkinson et al. 2003). All 
western blot analysis was performed three times for each analysis and 
representative blots presented.  The following primary antibodies were used for 
western blotting: Protein zero, MPZ, (1/1000, Sigma Aldrich SAB2500665), β-Tubulin 
(1/2000, Santa Cruz Biotechnology sc-134229). Antibodies to p38 alpha (#9218), 
p38 beta (#2339) and phospho-p38 (#4631), were all used at 1/500 were from Cell 
Signaling Technology.   
Statistical methods. 
All data shown is expressed as the mean ± Standard Error of the Mean (SEM). The 
statistical significance of any observed differences was assessed using the student’s 
t-test between the two groups of data. P values of <0.05 are indicated with an 
asterisk (*) on graphs. Where graphs are not labelled with an asterisk, any 
differences between groups of data were non-significant. 
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Due to the small sample sizes (n<5 for all comparisons), assumptions of how well 
normality and equal variances fit the data could not be reliably assessed. Sample 
size was not predetermined by statistical methods and randomisation was not 
applied. For functional testing by SSI, the evaluation of values was made by an 
individual blinded to the genotype of the animal. No samples or data were excluded 
from the analysis. The n number for each experiment has been stated in all Figure 
legends.  
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Results. 
Characterisation of peripheral nerves with Schwann cell-specific deletion of p38 
Our previous work and that of other groups to examine the role of p38 MAPK 
signalling in Schwann cells has relied upon the use of either chemical inhibitors, 
such as SB202190 or PD169316, combined with in vitro assays of myelination, or 
the use of genetically modified mice that have globally reduced, but not absent, p38 
MAPK activity in all cells of the PNS. These studies have seemingly identified both 
positive and negative control of myelination by p38 activity, plus effects upon axonal 
regeneration and remyelination (Yang et al. 2012, Myers et al. 2003, Kato et al. 2013, 
Hossain et al. 2012, Fragoso et al. 2003). Among the four isoforms of the p38 MAPK 
proteins, the p38 isoform is the major isoform expressed in rat Schwann cells and 
sciatic nerves (Figure 4A and (Hossain et al. 2012)). To determine the Schwann cell 
specific function of p38 MAPK in vivo, we chose to specifically delete the p38 
protein in Schwann cells and examine the effects upon peripheral nerve myelination 
and repair following injury. Deletion of the p38coding sequence was accomplished 
using the mP0TOTA-CRE line which induces Schwann cell-specific recombination in 
the PNS on or around embryonic day 13.5 in mouse development (Feltri et al. 1999). 
We first examined myelination in the mouse sciatic nerve at early post-natal 
timepoints. For samples of post-natal day (P) 2 nerve, we first identified Schwann 
cells that had sorted and were in a clear 1:1 relationship with an axon and then 
counted the proportion of these Schwann cells that had produced compact myelin. 
Samples from post-natal day (P) 2 from p38 null pups showed significantly higher 
percentage of Schwann cells that had produced compact myelin than their control 
11 
 
littermates (Figure 1 A-C); measurements of myelin also showed a small but non-
significant increase in myelin thickness at this age (Figure 1D).  
At P6, using both low vacuum scanning electron microscopy and transmission 
electron microscopy, we observed a shift in axons to having thicker myelin (Figure 2 
A-E), in support of our previous findings that p38 MAPK activity in Schwann cells is 
an inhibitor of myelination (Yang et al. 2012). For the percentage of axons with 
thicker myelin at this age (i.e. myelin thickness between 0.7-0.8 m), we observed a 
significant (P<0.05) increase in the p38 null nerves as compared to controls (Figure 
2E). 
 In our in vivo p38 null nerves, an increase in the myelin protein P-zero (MPZ) was 
also observed at P6 and the expected reduction of p38 expression confirmed by 
western blotting; we presume that the small residual p38 levels are from other cell 
types within the nerve.  No change in the level of the Sox10 protein was observed in 
vivo (Figure 2F), in contrast to the reduction  of Sox10 and block in myelination 
observed in vitro in Schwann cell/DRG neuron co-cultures with the p38 inhibitor 
PD169316 (Hossain et al. 2012, Fragoso et al. 2003). No apparent changes were 
observed in Schwann cell number, as assessed by nuclei counts of cryostat sections 
or any abnormalities in axon sorting, axon number or axon diameter in either P2 or 
P6 p38 null pups or adult animals as compared to controls (data not shown).  
Following on from this finding, we then analysed control and p38 null nerves at both 
P21 and P90 timepoints to check for whether we would observe increased levels of 
myelination at these timepoints. At both P21 and P90 we observed consistent, but 
small, increases in myelin thickness in the p38 null animals and a shift towards 
lower G ratio, however these changes were not significant at either P21 or P90 
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timepoints (at P90, G ratio for p38 nerves was 0.60±0.07 compared to 0.61±0.02 in 
control animals; Figure 3 A-F). We also observed no significant differences in 
numbers of myelinated fibres at P21 and P90 between control and p38 null animals 
(data not shown). 
 
p38 loss leads to slower myelin breakdown in Schwann cells following injury. 
Our previous work has shown that the p38 inhibitors SB202190 in vitro and 
SB203580 in vivo, block the down-regulation of myelinating Schwann cell markers 
expression following injury (Yang et al. 2012). We next tested whether loss of 
Schwann cell-expressed p38 had similar effects in vivo. Following nerve injury, we 
measured the loss of myelin protein expression by western blot. As previously 
described, nerve injury induces activation and phosphorylation of p38 (Myers et al. 
2003, Yang et al. 2012). Using a phospho-specific p38 antibody, which detects all 
phosphorylated isoforms of p38, we observed loss of signal for phospho-p38, 
indicating both the efficient loss of p38 in Schwann cells within the nerve and that 
p38 is the major isoform expressed and confirming that, within the nerve, Schwann 
cells activate the p38 MAPK pathway following injury (Yang et al. 2012, Myers et al. 
2003). Activation of ERK1/2 that occurs in Schwann cells following injury (Harrisingh 
et al. 2004) was unchanged in p38 null nerves (Figure 4B).  Expression of the 
myelin proteins myelin basic protein (MBP) and P-zero were unchanged in adult 
p38 null animals as compared to controls in intact nerve, but at 7 days after injury 
we observed higher levels of P-zero and MBP protein in the distal stumps of p38 
null animals, indicating a slower process of demyelination in Schwann cells lacking 
p38 (Figure 4C). Western blotting showed that loss of p38 does not cause any 
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compensatory changes in levels of the p38 isoform within the intact or injured nerve 
(Figure 4D). In line with our previous findings in vitro for regulation of cJun by the 
p38 MAPK pathway (Yang et al. 2012), we also observed some reduction in cJun 
expression, but not Sox2, in p38 null nerves following injury (Figure 4E).  
Although we observed a slower loss of myelin protein expression, axonal breakdown 
distal to the injury site appeared unchanged in p38 null nerves as compared to 
controls (Figure 4 F, G; 4d post-crush injury). In nerve transection experiments, in 
which a 0.5cm segment of nerve was removed between proximal and distal stump to 
prevent regeneration, complete loss of axons and myelin was observed in both 
control and p38 null nerves at 14d post-injury (Figure 4 H-K). These experiments 
indicate that although myelin breakdown is slower in p38 null nerves at earlier 
timepoints (7 days), the processes of Wallerian degeneration at later timepoints 
appear to have completed in both the p38 null and control nerves at 14 days post-
injury.   
 
Effects of p38 loss upon Schwann cell proliferation and macrophage recruitment 
following injury. 
Activation of the p38 MAPK pathway is associated with many different cell 
behaviours, including proliferation, survival and the control of the inflammatory 
response (Zarubin & Han 2005). Following PNS injury, there is a proliferation of 
Schwann cells distal to the injury site as well as the breakdown of the blood-nerve 
barrier and entry of macrophages into the distal nerve (Chen et al. 2007). In order to 
determine the effects of the loss of p38MAPK in Schwann cells in these events,  we 
next measured both Schwann cell proliferation by Sox10/Ki67 double labelling and 
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macrophage numbers by Iba1 immunolabelling at 7 days post transection injury in 
control and p38 distal null nerves.  
Double immunolabelling of nerve sections from both control and p38 null nerves 
with Sox10 and Ki67 antibodies showed that approximately 80% of proliferating Ki67 
positive cells in these sections were Sox10-positive Schwann cells (Figure 5 B-D and 
data not shown). No significant differences in numbers of Sox10 positive/Ki67 
positive or Sox10 negative/Ki67 positive cells were observed between control and 
p38 null nerves. Total numbers of Sox10/Ki67 positive cells per section were 
counted and showed that loss of p38 caused no significant change (p=0.80) in 
Schwann cell proliferation at this timepoint following injury (Figure 5A). Counts of 
Iba1-positive macrophages in distal p38 nerves also showed no significant 
differences to those seen in control nerves (p=0.44) (Figure 5E, F). 
 
Loss of p38 in Schwann cells has no effect upon axonal regeneration and 
functional repair. 
The use of mouse models with a global reduction of p38 MAPK activity and 
treatment of animals with p38 inhibitors has yielded very different results for the roles 
of p38 MAPK in axonal regeneration and functional repair (Myers et al. 2003, Kato et 
al. 2013). Use of the sevenmaker mouse mutant, with a proposed reduced p38 
activity in all cells of the nerve, showed a reduced rate of functional recovery, which 
was proposed to be due to an abnormal cytokine response (Kato et al. 2013). In 
contrast, use of the p38 MAPK inhibitor SD-169 administered to mice following a 
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nerve crush injury increased rates of axonal re-growth and re-myelination (Myers et 
al. 2003).    
Following PNS injury, Schwann cells distal to the site of injury re-program to a 
specialised repair-competent cell, or Büngner cell, which directs axonal regeneration, 
remyelination and allows functional repair (Jessen & Mirsky 2016, Arthur-Farraj et al. 
2012, Parkinson et al. 2008). We next carried out a series of experiments to 
determine the role of p38 and how loss of p38 MAPK function in Schwann cells 
would influence rates of axonal regeneration and remyelination following a crush 
injury to the sciatic nerve. Following such an injury, mice regain full functional repair 
after 21 days as measured by the static sciatic index (SSI) measure of sensorimotor 
recovery (Arthur-Farraj et al. 2012, Baptista et al. 2007).  
As previous work has identified an acceleration of axonal regrowth with p38 MAPK 
inhibition, using the chemical inhibitor SD-169 (Myers et al. 2003), we first used a 
wholemount staining protocol to measure the rate of axonal regeneration in control 
and p38 null animals following crush injury (Dun & Parkinson 2015). Neurofilament 
staining of the nerve at 5 and 7 days following crush injury showed that there was no 
significant difference in the rate of axonal growth in p38 null nerves as compared to 
control animals at 7days post-crush injury (Figure 6 A-C and data not shown). 
Measurements of SSI following nerve crush injury revealed no significant differences 
in recovery rate between control and p38 null animals at any of the timepoints 
tested up to 21 days (Figure 6D). 
Measurements of myelin thickness and G ratio, however, as during development, 
showed a slight, but not significant, increase in the myelin thickness of remyelinated 
fibres in the distal sciatic nerve at 21 days post-crush injury (G ratio p38 repaired 
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nerves 0.67±0.06; control repaired nerves 0.77±0.02; P=0.17) (Figure 6E-G). In 
contrast to the previous study using SD-169 (Myers et al. 2003), however, we 
observed no significant changes in the average diameter of myelinated regenerated 
axons in control and p38 null nerves at this timepoint (Figure 6I). 
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Discussion 
Schwann cells that myelinate the PNS possess the ability to reprogramme their 
function following injury to generate a specialised repair cell that allows axonal 
regeneration and functional repair (Kim et al. 2013, Jessen & Mirsky 2016). 
Research into the signalling mechanisms and transcriptional control that regulates 
both myelination during development and the cellular reprogramming of Schwann 
cells following injury has identified a number of positive and negative regulators of 
these processes, with genetic evidence for roles of many transcription factors such 
as Krox20, Sox10 and Oct6 in driving myelination and for cJun, Sox2 and Pax3 to 
negatively regulate myelination (Svaren & Meijer 2008, Doddrell et al. 2012); further 
research into the role of cJun identified it as crucial to the generation of the 
specialised repair or Büngner cells that drive functional repair following injury 
(Parkinson et al. 2008, Arthur-Farraj et al. 2012, Fontana et al. 2012, Jessen & 
Mirsky 2016).  
Evidence to date for the role of the p38 MAP kinase pathway has been contradictory, 
with some findings showing a requirement for this pathway to drive myelination in 
Schwann cells (Fragoso et al. 2003, Hossain et al. 2012)  and other studies showing 
that increased p38 activity inhibits myelination (Yang et al. 2012). These studies 
have been complicated by the use of either chemical inhibitors of the p38 pathway 
which are applied, often systemically or to in vitro mixed cell cultures (eg. 
DRG/Schwann cell co-cultures) and the requirement for p38 signalling in each cell 
type cannot be fully established (Hossain et al. 2012, Fragoso et al. 2003), in 
addition to the possible ‘off-target’ effects of such inhibitors (Davies et al. 2000, Godl 
et al. 2003, Bain et al. 2007).   
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Genetic approaches to reduce p38 activity, such as the sevenmaker or sem mouse, 
can only be analysed in the heterozygous state (due to embryonic lethality of p38 
null animals) and again are non-cell type specific with loss of p38 MAPK activity 
within all cell types within the nerve (Kato et al. 2013). To date, no study has 
specifically ablated p38 MAPK activity in Schwann cells alone and determined the 
effects upon PNS myelination and repair in vivo.  
In this study, using  Schwann cell-specific p38 null animals, we have systematically 
measured the effects of p38 function in the regulation of myelination at different 
developmental stages and events following PNS injury, namely myelin breakdown, 
Schwann cell proliferation, macrophage infiltration, axonal regeneration and 
functional repair of the nerve. From these analyses, we can confirm that, in vivo, p38 
MAPK does appear to negatively regulate both developmental myelination and 
myelin breakdown, but does not appear to regulate axonal regeneration or functional 
repair. 
Previous work using in vitro SC/DRG co-culture system using p38 inhibitors found 
that both Schwann cell-axon alignment and consequent myelination, induced by 
ascorbic acid addition to the cultures, required p38 activity (Fragoso et al. 2003, 
Hossain et al. 2012). In our own experiments, in order to distinguish between the 
early events of laminin-induced Schwann cell-axon alignment and the later induction 
of myelination, we added p38 inhibitors at 3 days after ascorbate addition and 
observed an enhancement of myelination in these cultures (Yang et al. 2012). The 
P0-CRE line used in our work would be expected to remove the p38 gene at E13.5 
in Schwann cells of the nerve (Feltri et al. 1999) and has been used to study the 
roles of several integrins in regulating laminin signalling,  axonal sorting and 
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myelination during PNS development (Pellegatta et al. 2013, Nodari et al. 2007, 
Feltri et al. 2002). It would seem probable that any effects of p38 MAPK loss upon 
Schwann cell-axon interaction and radial sorting would have been seen in our in vivo 
experiments at the timepoints examined, but none were apparent. Instead, we only 
observed an enhancement of myelination at post-natal days 2 and 6 in the p38 null 
nerves, supporting our idea that p38 MAPK is functioning as a negative regulator of 
myelination. 
Our finding of slightly increased remyelination following injury in p38 null nerves is 
in agreement with previous work using an in vivo regeneration chamber experiment 
in rat sciatic nerve using the SD-169 inhibitor (Myers et al. 2003), but our data 
identifies this effect as a Schwann cell-dependent role for p38 MAPK. However, in 
contrast to previous findings, we do not see effects of loss of p38 MAPK activity in 
Schwann cells upon the control of the rate of axonal regeneration or functional repair. 
The slight delay in myelin clearance from the distal nerve in p38 nulls does not 
seem to slow axonal regrowth or functional recovery in our experiments. Analysis of 
nerves at later timepoints following injury (14 days) shows that axonal breakdown 
and myelin loss are seemingly complete by this time in both control and p38 null 
nerves. Furthermore, we see no apparent changes in axonal fragmentation distal to 
the site of injury in p38 null nerves at earlier timepoints (4 days) post-injury. Thus 
although we see some delay in myelin clearance at 7 days post-injury, this early 
delay appears to correct in p38 null nerves and myelin debris, which otherwise may 
prevent axonal regeneration (Kang & Lichtman 2013, Zhang et al. 2013) does not 
hinder the functional recovery of p38 null animals.  In addition, we see no apparent 
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effects of p38 ablation upon the events of both macrophage recruitment or 
Schwann cell proliferation following injury.  
In conclusion, using Schwann cell-specific ablation of p38 in the peripheral nervous 
system we find that p38 MAPK activity does appear to play an inhibitory role in the 
control of myelination, both during development and remyelination following injury 
and the loss of myelin protein expression following injury.  However, we find no effect 
of the loss of Schwann cell-derived p38 MAPK activity in the regrowth of axons, 
functional recovery or other elements of Wallerian degeneration such as 
macrophage entry or Schwann cell proliferation following injury. As this study has for 
the first time used a Schwann cell-specific ablation of p38 MAPK, this would suggest 
these effects upon axonal regrowth and remyelination are due either to the 
contribution of p38 activity from other cell types within the nerve, such as neurons, 
macrophages or nerve fibroblasts, or to ‘off target’ effects of the p38 inhibitors used 
in these previous studies.   
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Figure legends 
Figure 1: Increased myelination in the nerves of p38 null mice at post-natal day (P) 
2. Transmission electron micrographs of sciatic nerve sections from control (A) and 
p38 null (B) P2 mouse pups. Arrows in panel A indicate Schwann cells in a 1:1 
relationship with an axon and arrowheads indicate Schwann cells that have 
produced compact myelin. Scale bar 5m. C. Graph showing a significant increase 
(P=0.02) in the percentage of axons myelinated in the nerves of p38 P2 animals 
compared to controls. D. Distribution graph showing a small shift in the percentage 
of axons with thicker myelin in p38 null animals compared to controls  
Figure 2:  Comparison of myelination in the nerves of p38 null and control mice at 
P6. A, B. Low vacuum scanning electron microscopy images of sciatic nerves from 
control (A) and p38 null (B) P6 mouse pups. Scale bars 50m. C, D. Transmission 
electron micrographs of sciatic nerve samples from control (C) and p38 null (D) P6 
mouse pups. Scale bars 5m E. Distribution graph showing a shift in percentage of 
axons having thicker myelin in p38 null nerves compared to controls. Comparison 
between control and p38 null nerves with myelin thickness between 0.7-0.8m 
shows significant increase (P<0.05) in p38 null nerves.  F. Western blot of control 
and p38 null P6 mouse nerve samples (n=3 pooled nerve samples, 1 pool=6 sciatic 
nerves from 3 mice for each genotype; experiments performed in triplicate and 
representative blot shown). Values given below MPZ blot samples represent 
normalised expression of p38 null samples against the control. -tubulin was used 
as loading control. 
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Figure 3: Measurements of myelin thickness in P21 and P90 in control and p38 null 
animals.  A, B. Transmission electron micrographs of P21 control (A) and p38 null 
(B) mouse nerves. Scale bar 5m C. Distribution graph showing percentage of axons 
and myelin thickness in control and p38 null P21 nerves. D. Scatter plot of G ratio 
versus axon diameter for control and p38 null P21 nerves. E. Distribution graph 
showing percentage of axons and myelin thickness in control and p38 null P90 
nerves. F. Scatter plot of G ratio versus axon diameter for control and p38 null P90 
nerves. For all data, n=3 for each mouse genotype. 
 
Figure 4: Western blot analysis of control and p38 null nerves before and following 
injury. A. Expression of p38 and p38isoforms in cultured rat Schwann cells and 
samples of post-natal day 2 (P2), P14 and adult (Ad) rat sciatic nerve. Kidney tissue 
(K) was used as a positive control for p38 and p38 protein expression. B. 
Reduction of phospho-p38, but not phospho-ERK1/2 at 3 days (d) following injury in 
control and p38 null nerves. C. Blot showing slower breakdown of P-zero (MPZ) 
and myelin basic protein (MBP) in the distal stumps of p38 null nerves in 
comparison to controls at 7d following transection injury. Values for MPZ and MBP 
for p38 null represent normalised expression against the control wild-type animal.  
D. Western blot of levels of p38 and p38 in control and p38 null intact and injured 
nerves (7d following nerve transection). E. Western blotting for cJun and Sox2 levels 
in control and p38 null intact and injured nerves (7d following nerve transection). 
For western blotting, n=1 mouse for each sample for both genotypes; experiments 
performed in triplicate and representative blot shown. -tubulin was used as loading 
control. 
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F, G. Wholemount immunolabelling of distal sciatic nerve at 4d following crush injury. 
Neurofilament staining shows equally fragmented axons in control (F) and p38 null 
(G) nerves. Scale bar 100m. H-K. Semi-thin sections of control (H, I) and p38 null 
(J, K) nerves at 14d following sciatic nerve transection injury. Images are shown for 
both distal sciatic (H, I) and tibial (J, K) nerves showing axonal loss and myelin 
breakdown at this timepoint in both control and p38 null nerves. Scale bar 75 m.  
Figure 5: Schwann cell proliferation and macrophage recruitment post transection 
injury in control and p38 null nerves. A. Counts of proliferating Sox10/Ki67 positive 
cells per section in distal sciatic nerve at 7 days post-injury. B-D. 
Immunofluorescence staining of control nerve sections with Ki67 (C) and Sox10 (D) 
antibodies. Arrows in C and D indicate Sox10/Ki67 double positive Schwann cells. 
Arrowhead in C and D indicates Sox10 negative/Ki67 positive cell. Cells were 
counterstained with Hoechst (Ho) to show nuclei (B). Scale bar 25m E. Labelling of 
control nerve section with Iba1 antibody, arrows indicate Iba1 positive macrophages. 
Nuclei are counterstained with Hoechst dye (Ho). Scale bar 50 m F. Counts of Iba1 
positive cells per section in control and p38 null distal sciatic nerves 7d post-injury. 
For all data, n=3 for each mouse genotype. 
 
Figure 6: Axon regrowth and functional recovery in control and p38 null nerves. A, 
B. Representative wholemount images of control (A) and p38 null (B) nerves at 7d 
following crush injury immunolabelled with neurofilament antibody to reveal 
regrowing axons. Arrows in panels A and B to the left show the position of the crush 
25 
 
site.  Scale bar A and B 1mm. A’ and B’ show higher magnifications of boxed areas 
in panels A and B of control (A’) and p38 null (B’)  nerves with the furthest 
regrowing axons marked by an arrowhead. Scale bar A’ and B’ 100m. C. Graph of 
distance of furthest axon from crush site in control and p38 null nerves at 7d post-
injury. D. Measurements of functional recovery by SSI analysis in control and p38 
null mice up to 21d after crush injury. E, F. TEM images of distal sciatic nerve from 
control (E) and p38 null (F) animals at 21d post-crush injury. G. Scatter plot of G 
ratio vs axon size at 21d post-crush injury. H Average G ratios for control and p38 
null nerves at 21d post-crush injury showing a small, but non-significant, reduction in 
G ratio in repaired p38 null nerves. I. Average axon diameter of myelinated fibres in 
distal sciatic nerve of repaired control and p38 null nerves at 21d post-crush injury. 
For all data, n=3 for each mouse genotype.  
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List of Abbreviations. 
Oct6: Octamer-Binding Transcription Factor 6 
YY1: Ying Yang 1 
NFATc4: Nuclear Factor of Activated T-cells c4 
ERK1/2: Extracellular signal-regulated kinases ½ 
DRG: Dorsal Root Ganglion 
PBS: Phosphate Buffered Saline 
MAPK: Mitogen Activated Protein Kinase 
MPZ: Myelin Protein Zero 
MBP: Myelin Basic Protein.  
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